Is Pawpaw Good for Diabetics?

Papaya, widely known as “pawpaw” across much of Africa, the Caribbean, and Australia, is generally a reasonable fruit for people managing diabetes, though the details matter more than a simple yes or no. Ripeness, portion size, and how the fruit is prepared all shift its effect on blood sugar. Beyond just being a fruit you can eat, papaya and its various plant parts contain compounds that researchers are actively studying for potential blood-sugar-lowering properties, and some early human data is genuinely encouraging.

Which Fruit Are We Talking About?

Before anything else, it helps to clear up a naming issue. In most of the world, “pawpaw” refers to Carica papaya, the soft, orange-fleshed tropical fruit. In North America, “pawpaw” means Asimina triloba, a completely different custard-like fruit native to the eastern United States. The two are unrelated, have different nutritional profiles, and carry different considerations for someone with diabetes. Most of the research relevant to diabetes involves Carica papaya, and that is the main focus here. The North American pawpaw gets its own section later because it raises a separate set of questions.

How Papaya Affects Blood Sugar

The glycemic index of papaya varies more than you might expect, and ripeness is one of the biggest reasons why. A 2025 study measuring glycemic responses in healthy volunteers found that ripe papaya had a low GI, while very ripe papaya jumped to about 57, placing it in the intermediate GI category.¹ That is a meaningful swing just from letting the fruit sit on the counter a few extra days. The glycemic load, which accounts for how much carbohydrate you actually eat in a typical serving, stayed low to moderate even for the very ripe fruit.

However, an older study that tested blood glucose responses specifically in people with type 2 diabetes found a much higher GI for papaya, around 86, which would put it in the high category alongside white bread.² That study also found papaya produced a higher glycemic response than mango and chico (sapodilla), both of which came in under 60. The gap between these two findings is large, and it likely comes down to papaya variety, ripeness stage, the population tested, and how the test portions were standardized. People with diabetes tend to have exaggerated blood sugar responses to the same foods compared to people without diabetes, which could partly explain the discrepancy.

A study conducted among people with type 2 diabetes in Nigeria offers a more reassuring picture. In that trial, pawpaw produced a blood glucose rise of roughly 31 mg/dL, considerably lower than pineapple at about 90 mg/dL and watermelon at about 102 mg/dL.³ The researchers concluded that pawpaw and banana were more suitable for glycemic control than pineapple or watermelon.

The takeaway from these mixed results: papaya is not a uniformly “safe” or “dangerous” fruit for blood sugar. If you pick it up when it is barely ripe and eat a moderate portion, you are looking at a gentle glycemic response. If it is very ripe, mushy, and intensely sweet, expect more of a spike, especially if you eat a large amount on an empty stomach. Among common tropical fruits, it tends to fall somewhere in the middle, with watermelon and pineapple generally producing sharper rises and lower-sugar fruits like guava or berries performing better.

Enzyme Inhibition and How Papaya Compounds Slow Sugar Absorption

One of the more interesting findings about papaya involves its ability to interfere with the digestive enzymes that break down starches and sugars. Two enzymes in particular, alpha-amylase and alpha-glucosidase, are responsible for chopping complex carbohydrates into simple sugars that enter your bloodstream. Drugs like acarbose work by blocking these enzymes, and papaya extracts appear to do something similar, albeit less potently.

Extracts from papaya seeds showed moderate inhibitory activity against both alpha-amylase and alpha-glucosidase in laboratory tests, with the hexane extract performing best among the solvents tested.⁴ Separately, dried extracts of Chilean papaya were evaluated for their effect on alpha-glucosidase and showed enough potency to be considered potentially useful for regulating glucose metabolism in people with type 2 diabetes.⁵ The practical implication is that eating papaya alongside starchy foods could slow the rate at which those starches convert to glucose, blunting the post-meal blood sugar peak. That said, these are lab and animal findings, and nobody has confirmed the strength of this effect in a controlled human feeding study.

What Happens in Human Studies

The most distinctive human data involves fermented papaya preparation, a commercial supplement made by fermenting the whole fruit. In one study of type 2 diabetic patients, taking fermented papaya preparation led to a significant decrease in plasma sugar levels. The drop was clinically meaningful enough that some diabetic patients in the study reduced their oral diabetes medication, and one patient stopped it entirely.⁶ That is a striking result, though the study was small, and the blood sugar drop was described as a “collateral effect” rather than the primary outcome being studied.

A randomized trial in Mauritius tested 6 grams of fermented papaya preparation daily for 14 weeks. The researchers found significant improvements in C-reactive protein (a marker of inflammation), the LDL-to-HDL cholesterol ratio, and uric acid levels compared to the control group.⁷ These are not blood sugar numbers directly, but they are markers that track with cardiovascular risk and the kind of chronic inflammation that makes diabetes progressively more damaging. The researchers suggested fermented papaya could be a feasible nutraceutical for managing diabetes and reducing the risk of complications worsened by oxidative stress.

A review of the broader evidence noted that papaya fruit consumed after meals significantly reduced blood glucose in a quasi-experimental study, and that the fruit, leaves, and seeds have all shown antidiabetic properties across different types of research.⁸ What is still missing is a large, long-term clinical trial testing fresh papaya consumption in a well-controlled setting. The evidence so far is promising but scattered across small studies and fermented preparations that differ from eating a slice of ripe fruit.

Beyond the Fruit Flesh

Much of the diabetes research on papaya does not actually involve eating the fruit at all. The leaves, seeds, and even the peel have drawn attention as sources of bioactive compounds, largely in animal studies. While you would not necessarily brew papaya leaf tea based on rat data, the consistency of the findings across multiple labs is worth understanding.

Papaya leaf extract given to diabetic rats for 30 days produced significant drops in blood glucose at several doses, compared to untreated diabetic animals.⁹ A separate study found that chloroform extract of papaya leaves had both blood-sugar-lowering and lipid-lowering effects in diabetic rats, with the researchers attributing the activity to steroid compounds that may slow glucose and lipid absorption in the gut.¹⁰ A third study confirmed reductions in blood glucose and improvements in lipid profiles at higher doses of leaf extract.¹¹

Perhaps most intriguingly, papaya leaf extract appears to protect the insulin-producing beta cells of the pancreas. In one study, administering the extract to diabetic rats preserved the number and structure of pancreatic islets and improved fasting blood sugar. When the extract was added to pancreatic cells in culture alongside a chemical that destroys beta cells, insulin output was higher than in cells exposed to the chemical alone.¹² If that effect translated to humans, it would not just manage symptoms but could help preserve the pancreas’s ability to make insulin, which is a fundamentally different kind of benefit. Whether it translates remains an open question.

Protecting Against Diabetic Complications

Diabetes does its worst damage slowly, and much of that damage stems from oxidative stress hammering organs like the kidneys, eyes, and nerves over years. Some of the papaya research has specifically looked at whether the plant’s antioxidant properties can protect against these downstream problems.

A study on diabetic kidney damage found that papaya leaf fractions, particularly the n-hexane fraction, restored key antioxidant enzymes to near-normal levels while reducing a marker of oxidative damage. Untreated diabetic rats showed severe kidney damage on histological examination, while those given papaya leaf fractions had varying degrees of protection.¹³ Kidney disease is one of the most common and feared complications of diabetes, so even the possibility of a protective effect from a widely available plant is worth noting.

On a different front, papain, the enzyme that gives papaya its meat-tenderizing reputation, has found a practical use in treating diabetic foot ulcers. A study comparing papain-urea ointment to hydrogen peroxide for wound debridement in diabetic foot ulcers found that papain-urea was significantly better at reducing ulcer size, removing dead tissue, and promoting new tissue growth, all without complications.¹⁴ This is not about eating papaya but about using one of its compounds as a topical treatment, and it is one of the more direct clinical applications of papaya in diabetes care.

Fiber, Gut Bacteria, and the Indirect Blood Sugar Connection

Dietary fiber from papaya does more than slow digestion in the stomach. It also reaches the colon, where gut bacteria ferment it and produce short-chain fatty acids. These fatty acids have their own set of metabolic effects, including improving insulin sensitivity and signaling the gut to release hormones that help regulate blood sugar.

Laboratory fermentation experiments using dietary fibers extracted from both unripe and ripe papaya pulp showed that these fibers stimulated production of short-chain fatty acids and were used differently by various gut bacterial populations.¹⁵ Fibers from unripe papaya, which are more structurally complex, were broken down differently than those from ripe papaya, suggesting that the ripeness of the fruit you eat may influence which gut bacteria benefit most.

A study that took this a step further used a fiber product made from papaya peel and tested it in diabetic rats. The fiber contributed to lower blood glucose by increasing the viscosity of food in the gut, slowing nutrient absorption, and promoting short-chain fatty acid production through bacterial fermentation.¹⁶ This is part of a growing body of research suggesting that the fiber in fruits matters as much as the sugar content when you are thinking about blood glucose management. Eating whole papaya gives you that fiber; drinking papaya juice strips most of it away.

Practical Tips for Eating Papaya With Diabetes

If you have diabetes and want to include papaya in your diet, a few practical points emerge from the research. Choosing fruit that is ripe but not overly soft or mushy keeps the glycemic index lower. Very ripe papaya, where the flesh is almost liquid and intensely sweet, pushes the GI into intermediate or potentially high territory, depending on the variety.¹ Sticking to a portion of about a cup (roughly 140 grams) keeps the glycemic load low regardless of ripeness.

Pairing papaya with a source of protein or fat, as you would with any higher-carbohydrate food, slows the gastric emptying rate and blunts the blood sugar spike. Eating it as part of a meal rather than on its own produces a gentler curve. And because the fiber content of papaya is relatively modest compared to fruits like guava or berries, you get less of that built-in brake on sugar absorption, which is another reason portion awareness matters.

It is also worth flagging a caution for anyone on blood-sugar-lowering medication. The fermented papaya study mentioned earlier found that diabetic patients lowered or even stopped their oral diabetes drugs because of an unexpected blood sugar drop.⁶ If you start taking a concentrated papaya supplement, monitor your blood sugar more closely and talk to your doctor about potential interactions, especially if you are on sulfonylureas or insulin, which can cause dangerously low blood sugar when combined with additional glucose-lowering effects.

The North American Pawpaw Is a Different Story

If you are in the United States and thinking of Asimina triloba, the native pawpaw with the banana-custard flavor, the picture changes substantially. This fruit has received far less diabetes-specific research, and its nutritional profile differs from tropical papaya in ways that matter.

Ripe North American pawpaw fruit is high in sugar, particularly sucrose. Analysis of ripe fruit found sucrose at roughly 9,321 mg per 100 grams, making up about 70% of total free sugars. Sucrose in the ripe fruit was approximately 12 times higher than in the unripe fruit.¹⁷ That makes ripe North American pawpaw a fairly sugar-dense fruit, and without published glycemic index data specific to this fruit, people with diabetes should treat it with caution and keep portions small.

There is also a toxicity consideration that does not apply to papaya. North American pawpaw contains annonacin, a compound that has shown neurotoxic effects in laboratory studies. Research measuring annonacin levels in the fruit pulp found an average concentration of about 0.07 mg/g, and purified annonacin killed half of cortical neurons in culture at relatively low concentrations after 48 hours of exposure.¹⁸ This does not mean eating a few pawpaw fruits is going to damage your brain, but it does mean that heavy, regular consumption of Asimina triloba raises questions that do not exist for Carica papaya. Other members of the Annonaceae family have been linked to atypical parkinsonism in populations that eat them frequently, and while the evidence for North American pawpaw specifically is not definitive, people with diabetes who already face elevated neurological risk may want to keep this on their radar. Occasional enjoyment of the fruit during its short fall season is probably not a concern; making it a dietary staple is a different matter.